ArticleAntimicrobial agents and chemotherapy2006
In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in Southern Québec, Canada.
Article in Antimicrobial agents and chemotherapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 98 citations in OpenAlex.
- Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: a systematic review and meta-analysis.Antimicrobial resistance and infection control · 2020Pooled it
- Molecular epidemiology ofMicrobiology spectrum · 2026Article
- Molecular epidemiology and antimicrobial resistance profiles ofFrontiers in microbiology · 2026Article
- An epidemiological surveillance study (2021-2022): detection of a high diversity of Clostridioides difficile isolates in one tertiary hospital in Chongqing, Southwest China.BMC infectious diseases · 2023Article
- Clostridioides difficile carriage in animals and the associated changes in the host fecal microbiota.Anaerobe · 2020Article
- Designed Ankyrin Repeat Protein (DARPin) Neutralizers of TcdB from Clostridium difficile Ribotype 027.mSphere · 2019Article
- Evidence of transmission of Clostridium difficile in asymptomatic patients following admission screening in a tertiary care hospital.PloS one · 2019Article
- Diagnosis ofIranian journal of microbiology · 2018Article
- Simultaneous detection and characterization of toxigenic Clostridium difficile directly from clinical stool specimens.Frontiers of medicine · 2018Article
- Review
- Molecular Epidemiology of Clostridium difficile Infection in Hospitalized Patients in Eastern China.Journal of clinical microbiology · 2017Article
- Article
- Predominance and high antibiotic resistance of the emerging Clostridium difficile genotypes NAPCR1 and NAP9 in a Costa Rican hospital over a 2-year period without outbreaks.Emerging microbes & infections · 2016Article
- Targeting surface-layer proteins with single-domain antibodies: a potential therapeutic approach against Clostridium difficile-associated disease.Applied microbiology and biotechnology · 2015Article
- Molecular Epidemiology of Clostridium difficile Infection in a Large Teaching Hospital in Thailand.PloS one · 2015Article
- Clinical update for the diagnosis and treatment of Clostridium difficile infection.World journal of gastrointestinal pharmacology and therapeutics · 2014Review
- Clostridium difficile infection: molecular pathogenesis and novel therapeutics.Expert review of anti-infective therapy · 2014Review
- Antimicrobial susceptibility of clostridium difficile clinical isolates in iran.Iranian Red Crescent medical journal · 2013Article
- Clostridium difficile 027/BI/NAP1 encodes a hypertoxic and antigenically variable form of TcdB.PLoS pathogens · 2013Article
- Characterization of a stable, metronidazole-resistant Clostridium difficile clinical isolate.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clostridium difficile isolates from a 2004 outbreak in Québec, Canada, were all found to be susceptible to metronidazole, vancomycin, rifampin, and meropenem but resistant to bacitracin, cefotaxime, ciprofloxacin, and levofloxacin, and most (>80%) were resistant to ceftriaxone, clarithromycin, gatifloxacin, and moxifloxacin. The predominant NAP1 isolates were susceptible to clindamycin, while the NAP2 isolates were resistant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.